Traditionally, the combination of OAC with dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) - commonly referred to as triple antithrombotic therapy (TTT) - was considered the standard of care for patients with AF undergoing PCI [4]. This evidence concerns the gene P2RY12 and atrial fibrillation.